SpectraCure's new generation of the treatment system Q-PRO^® and the integrated ultrasound image management technology from MedCom in Germany, has previously been approved by the FDA for use in the clinical study for the treatment of recurrent prostate cancer. The first treatment has now been performed with Q-PRO^® and the new integrated image management technology. The treatment was performed at Memorial Sloan Kettering Cancer Center in New York. The procedure went according to plan and the system met the high-set expectations very well. 

"It is significant that we have now completed the procedure and are up and running with Q-PRO^® together with MedCom's image management technology, for inserting optical fibers into the prostate. In addition, it is very satisfying that we received concrete evidence of the benefits of the integrated image management technology", says SpectraCure's CEO Johan Folkunger.

The new image management technology from MedCom, integrated with the IDOSE^®-platform, implies an improvement and simplification for the doctors. The software has advanced graphical aids which make the process faster and more efficient.

For further information: 
SpectraCure AB (publ) Johan Folkunger, CEO
E-mail: jf@spectracure.com
Website: www.spectracure.com

SpectraCure is developing a treatment system for the elimination of internal solid cancer tumors. We are initially focusing on recurrent prostate cancer, with the hope of being able to treat other cancers such as primary prostate cancer, breast cancer, pancreatic cancer, and head and neck cancer in the future. The approach is based on a proprietary and patented treatment system, Q-PRO®, consisting of a hardware device, a laser unit, which performs PDT treatment and treats the prostate itself, combined with a software device, the patented IDOSE® dose planning platform. The method allows the laser light dose to be controlled so that the tumor is exposed to an optimal dose to achieve sufficient treatment effect. The treatment system has the potential to make interstitial PDT treatment accurate, precise, and safe for every patient. The goal is that in addition to being tumor-free, the patient will be able to maintain their quality of life, with limited side effects. We are conducting clinical trials as an important part of the continued development of the company's treatment system. 

The company is listed in the Premier segment of the Nasdaq First North Growth Market with G&W Fondkommission as Certified Adviser, and trades under the short name SPEC.